bluebird bio to pay $30 million upfront for 10 of Gritstone's tumor-specific targets and T-cell receptors (Image: Gritstone Oncology).
Regeneron also investing $100 million in bluebird bio at 59% premium to Aug. 3rd closing price.
Boosting autophagy -- cells breaking down and recycling components -- to stop disease (Image: Britannica)
Company chart and information is provided by TradingView based on 15-minute-delayed data.
bluebird bio inc is a clinical-stage biotechnology company that develops gene therapies for severe genetic and rare diseases. The company's gene therapy procedures aim to genetically modify a patient's cells to fundamentally correct or address the genetic basis underlying a disease. Bluebird's revenue is derived from collaboration arrangements, research fees, license fees, and grant revenue. The company works with industry peers, strategic partners, and nonprofit organizations for the development and commercialization of its product candidates.
| Website: | www.bluebirdbio.com |
| Email: | IGoldberg@bluebirdbio.com |
| Main Phone: | +1 339 499-9300 |
| Address: | 60 Binney Street |
| Address 2: | P.O Box 1900, Station M |
| State: | MA |
| City / Town: | Cambridge |
| Country: | US |
| Postal Code: | 02142 |
| Exchange: | NGS |
| CEO: | Nick Leschly |
| Employees: | 1213 |
| NAICS: | Biological Product (except Diagnostic) Manufacturing(325414) |
bluebird bio to pay $30 million upfront for 10 of Gritstone's tumor-specific targets and T-cell receptors (Image: Gritstone Oncology).
Regeneron also investing $100 million in bluebird bio at 59% premium to Aug. 3rd closing price.
Boosting autophagy -- cells breaking down and recycling components -- to stop disease (Image: Britannica)
Targeting cellular senescence with programs in musculoskeletal, ophthalmologic and pulmonary disorders.
Cellular Biomedicine Group is developing therapies to treat cancer and other degenerative diseases in China.
Cambridge, Massachusetts-based bluebird bio (BLUE) soared to an all-time intraday high in Monday action after releasing positive preliminary clinical trial data for its experimental gene therapy
2013 was a banner year for the life sciences sector, with biotech, pharmaceutical and medtech companies buoyed by advances in therapeutic techniques, a friendly regulatory environment, lucrative
It’s all about the “cliff” and the market is saying –“no sweat.” However IMHO, odds favor the market beginning a correction shortly, or on the day a deal is announced.The correction
| Last Price N/A | Change $ N/A | Change % N/A | Tick N/A |
| Bid N/A | Bid Size N/A | Ask N/A | Ask Size N/A |
| Open N/A | High N/A | Low N/A | Prev Close N/A |
| Last Trade | Volume N/A | 52 Wk Hi N/A | 52 Wk Low N/A |
| Market Cap N/A | Ex-Div Date N/A | Div Rate N/A | Yield N/A |
| Shares N/A | EPS (TTM) N/A | PE Ratio N/A | Exchange N/A |
© 2022 Equities News | Equities.com, Inc.
* All dates and time are being displayed in Eastern Standard Time (EST).
